Back to Browse Journals » Breast Cancer: Targets and Therapy » Volume 3

Estrogen receptor (ER) and progesterone receptor (PgR) in breast cancer of Indian women

Authors Patil AV, Bhamre RS, Singhai R, Tayade MB, Patil VW

Published 19 April 2011 Volume 2011:3 Pages 27—33


Review by Single-blind

Peer reviewer comments 2

This paper has been retracted.
Amit V Patil1, Rahul S Bhamre2, Rajeev Singhai3, Mukund B Tayade4, Vinayak W Patil3
1Department of General Surgery, Government Medical College, Miraj, Maharashtra, India; 2Department of General Surgery, DY Patil Hospital and Research Centre, Nerul, Navi Mumbai, India; 3Department of Biochemistry, Grant Medical College and Sir JJ Group of Hospitals Mumbai, India; 4Department of General Surgery, Grant Medical College and Sir JJ Group of Hospitals Mumbai, India

Objective: To determine the expressions and relationship between estrogen receptors (ERs) and progesterone receptors (PgRs) in breast cancer in Indian women.
Participants: Surgically removed breast cancer tissues were collected from Grant Medical College and Sir JJ Group of Hospitals, Mumbai, India, taking (n = 300) cases of infiltrating duct cancer of Indian women after radical mastectomy and lumpectomy; the age- and menopausal-related subgroups satisfied this requirement.
Measurements: Statistical significance was calculated by the likelihood ratio test; relative risk served to check for significant differences. Relapse-free interval probabilities were calculated according to Kaplan and Meier, with Cox–Mantel test comparing survival functions and P values.
Results: We observed that only in middle-aged postmenopausal patients bearing pT2 tumors were ER and PgR receptors shown to have a prognostic significance with the lowest tested cutoff value being 5 fmol/mg.
Conclusion: Immunohistochemistry analysis has been shown to be a prognostic factor for patients with breast cancer; the major aim of determining the ER receptor status is to assess predictive response to hormonal therapy.

Keywords: prognostic cancer tissue biomarkers, immunohistochemistry, hormone receptors, steroid receptors

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] View Full Text [HTML] 


Other articles by this author:

The p53 breast cancer tissue biomarker in Indian women

Patil V, Tayade M, Pingale S, Dalvi S, Rajekar R, Deshmukh H, Patil S, Singhai R

Breast Cancer: Targets and Therapy 2011, 3:71-78

Published Date: 11 August 2011

Cancer biomarker HER-2/neu in breast cancer in Indian women

Singhai R, Patil VW, Patil AV

Breast Cancer: Targets and Therapy 2011, 3:21-26

Published Date: 29 March 2011

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women

Vinayak W Patil, Rajeev Singhai, Amit V Patil, et al

Breast Cancer: Targets and Therapy 2011, 3:9-19

Published Date: 16 March 2011

Readers of this article also read:

Evaluation of glycine-bearing celecoxib derivatives as a colon-specific mutual prodrug acting on nuclear factor-κB, an anti-inflammatory target

Lee S, Lee Y, Kim W, Nam J, Jeong S, Yoo JW, Kim MS, Moon HR, Jung Y

Drug Design, Development and Therapy 2015, 9:4227-4237

Published Date: 7 August 2015

Optical imaging for breast cancer prescreening

Godavarty A, Rodriguez S, Jung YJ, Gonzalez S

Breast Cancer: Targets and Therapy 2015, 7:193-209

Published Date: 20 July 2015

The role of peroxiredoxin II in chemoresistance of breast cancer cells

Wang T, Diaz AJG, Yen Y

Breast Cancer: Targets and Therapy 2014, 6:73-80

Published Date: 23 May 2014

PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysis

Liu YR, Jiang YZ, Zuo WJ, Yu KD, Shao ZM

OncoTargets and Therapy 2014, 7:543-552

Published Date: 10 April 2014

Pelvic schwannoma in the right parametrium

Machairiotis N, Zarogoulidis P, Stylianaki A, Karatrasoglou E, Sotiropoulou G, Floreskou A, Chatzi E, Karamani A, Liapi G, Papakonstantinou E, Katsikogiannis N, Courcoutsakis N, Machairiotis C

International Journal of General Medicine 2013, 6:123-126

Published Date: 8 March 2013

Williams–Campbell syndrome: a case report

Konoglou M, Porpodis K, Zarogoulidis P, Loridas N, Katsikogiannis N, Mitrakas A, Zervas V, Kontakiotis T, Papakosta D, Boglou P, Bakali S, Courcoutsakis N, Zarogoulidis K

International Journal of General Medicine 2012, 5:41-44

Published Date: 11 January 2012

Effects of low-dose tacrolimus therapy in combination with methotrexate in patients with methotrexate-refractory rheumatoid arthritis

Takeo Isozaki, Michihito Sato, Ryo Takahashi, et al

Open Access Rheumatology: Research and Reviews 2010, 2:29-34

Published Date: 6 July 2010